Incorporating data from various trial designs into a mixed treatment comparison model S Schmitz, R Adams, C Walsh Statistics in medicine 32 (17), 2935-2949, 2013 | 119 | 2013 |
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian … S Schmitz, R Adams, CD Walsh, M Barry, O FitzGerald Annals of the rheumatic diseases 71 (2), 225-230, 2012 | 114 | 2012 |
Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis R Adams, C Walsh, D Veale, B Bresnihan, O FitzGerald, M Barry Pharmacoeconomics 28, 477-487, 2010 | 70 | 2010 |
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ... Frontiers in pharmacology 11, 591134, 2021 | 65 | 2021 |
The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis S Schmitz, R Adams, C Walsh BMC medical research methodology 12, 1-17, 2012 | 39 | 2012 |
Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D E Fogarty, C Walsh, R Adams, C McGuigan, M Barry, N Tubridy Multiple Sclerosis Journal 19 (9), 1190-1196, 2013 | 38 | 2013 |
Understanding the challenges and uncertainties of seroprevalence studies for SARS-CoV-2 D McConnell, C Hickey, N Bargary, L Trela-Larsen, C Walsh, M Barry, ... International Journal of Environmental Research and Public Health 18 (9), 4640, 2021 | 32 | 2021 |
Identifying and revealing the importance of decision-making criteria for health technology assessment: a retrospective analysis of reimbursement recommendations in Ireland S Schmitz, L McCullagh, R Adams, M Barry, C Walsh Pharmacoeconomics 34, 925-937, 2016 | 31 | 2016 |
Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation D Issa, B Eghtesad, NN Zein, L Yerian, M Cruise, N Alkhouri, R Adams, ... International journal of organ transplantation medicine 7 (1), 38, 2016 | 26 | 2016 |
Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma A Schritz, N Aouali, A Fischer, C Dessenne, R Adams, G Berchem, ... Neuro-Oncology Advances 3 (1), vdab052, 2021 | 22 | 2021 |
Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients V Gimeno-Ballester, J Mar, A O’Leary, R Adams, R San Miguel Expert Review of Gastroenterology & Hepatology 11 (1), 85-93, 2017 | 20 | 2017 |
Health-related quality of life of HIV-infected intravenous drug users S Surah, R Adams, L Townsend, I Reynolds, JC Kinahan, S Keating, ... International journal of STD & AIDS 24 (11), 867-874, 2013 | 20 | 2013 |
A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS) D Wall, N Meah, K York, B Bhoyrul, L Bokhari, LS Abraham, R Adams, ... JAMA dermatology 157 (4), 439-448, 2021 | 16 | 2021 |
Evaluating the neonatal BCG vaccination programme in Ireland C Usher, R Adams, S Schmitz, J Kieran, D O’Flanagan, J O’Donnell, ... Archives of Public Health 74, 1-12, 2016 | 13 | 2016 |
Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements HG Eichler, R Adams, E Andreassen, P Arlett, M Van de Casteele, ... International Journal of Technology Assessment in Health Care 37 (1), e83, 2021 | 11 | 2021 |
The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort R Adams, BM Craig, CD Walsh, DJ Veale, B Bresnihan, O FitzGerald, ... Value in Health 14 (6), 921-927, 2011 | 9 | 2011 |
Using the analytic hierarchy process to derive health state utilities from ordinal preference data BP Reddy, R Adams, C Walsh, M Barry, P Kind Value in Health 18 (6), 841-845, 2015 | 8 | 2015 |
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis D McConnell, M Harte, C Walsh, D Murphy, A Nichol, M Barry, R Adams Scientific Reports 12 (1), 17561, 2022 | 7 | 2022 |
An evaluation of research replication and market segmentation with Q method RC Adams Operant Subjectivity 6 (4), 1983 | 7 | 1983 |
Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors S Spillane, C Usher, K Bennett, R Adams, M Barry Journal of Pharmaceutical Policy and Practice 8 (sup1), O10, 2015 | 6 | 2015 |